Glucagon-Like Peptides

Glucagon-Like Peptides
Accession Number

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

DrugDrug Description
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
TeduglutideA glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support.
AlbiglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
TaspoglutideTaspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted...
rGLP-1Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2.
BPI-3016BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).
Drugs & Drug Targets
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideSerum albumincarrier
TeduglutideGlucagon-like peptide 2 receptortarget
AlbiglutideGlucagon-like peptide 1 receptortarget